Nebivolol Eg

Active Ingredient:: Nebivolol
Origin:: EU

Nebivolol Eg (Nebivolol)

Q: What is Nebivolol Eg used for?

Nebivolol Eg contains the beta‑blocker nebivolol and is prescribed to lower high blood pressure in adults. It may also be used as part of therapy for certain forms of heart failure and chronic stable angina, depending on the treating physician’s assessment.

Q: How does nebivolol work to lower blood pressure?

Nebivolol selectively blocks β1‑adrenergic receptors, reducing heart rate and contractility, which lowers cardiac output. It also enhances nitric oxide release from the endothelium, causing vasodilation that further decreases systemic vascular resistance and blood pressure.

Q: What is the usual dose of Nebivolol Eg?

The dosage of Nebivolol Eg is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function and other medications. Patients should follow the exact dosing instructions provided by their healthcare professional.

Q: Is Nebivolol safe to use during pregnancy or breastfeeding?

The safety of nebivolol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Q: How do I order Nebivolol Eg from GNH India?

To place an order, submit an enquiry on the Nebivolol Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Nebivolol compare with other antihypertensive beta‑blockers?

Nebivolol is distinguished by its combined β1‑blockade and nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability compared with non‑vasodilating beta‑blockers such as atenolol or metoprolol. Clinical choice depends on individual patient characteristics and physician preference.

Q: What are the recommended storage conditions for Nebivolol Eg?

Nebivolol Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain its stability and potency.

Q: How is Nebivolol Eg administered?

Nebivolol Eg is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Q: What are the most serious risks associated with Nebivolol Eg?

Serious adverse events can include severe bradycardia, heart block, bronchospasm in patients with asthma or COPD, and rare cases of hepatic dysfunction or allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as fainting, severe shortness of breath, or rash with swelling.

Q: Who should not use Nebivolol Eg?

Nebivolol Eg is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or severe asthma/COPD unless a specialist advises otherwise.

Nebivolol, the active ingredient in Nebivolol Eg, is a beta blocker presented as a tablet for oral use. It lowers blood pressure in adults with primary hypertension and is classified under ATC code C07AB12.
GNH India supplies Nebivolol Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions, primarily hypertension.

Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension.
Heart failure (reduced ejection fraction): may improve cardiac output when incorporated into guideline‑directed therapy.
Chronic stable angina: can decrease myocardial oxygen demand and relieve chest discomfort.

How It Works

Nebivolol selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which lowers cardiac output and systemic blood pressure. In addition, it stimulates endothelial nitric oxide synthase, promoting nitric oxide‑mediated vasodilation that further contributes to blood pressure reduction without significant β2 blockade.

Side Effects

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

Headache: mild to moderate intensity.
Dizziness or light‑headedness, especially after the first dose.
Fatigue or tiredness.
Nausea or mild gastrointestinal upset.
Bradycardia: heart rate slower than usual.
Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects

Severe bradycardia or heart block requiring medical attention.
Acute bronchospasm in patients with asthma or COPD.
Allergic reactions such as rash, pruritus, or angioedema.
Hepatic dysfunction indicated by elevated liver enzymes.
Cardiogenic shock in patients with advanced heart failure.

Precautions & Warnings

Before initiating Nebivolol therapy, clinicians should consider several safety aspects.

Blood pressure monitoring: ensure adequate control and avoid hypotension.
Heart rate assessment: avoid use in patients with resting bradycardia (<50 bpm).
Respiratory caution: use carefully in asthma or chronic obstructive pulmonary disease.
Discontinuation: taper gradually to prevent rebound hypertension.
Concomitant beta‑blockers: avoid additive effects that may cause excessive bradycardia.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Nebivolol may interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

Other beta‑blockers: additive negative chronotropic effects.
Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): may cause severe bradycardia.
Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, raising risk of hypotension.

Anti‑arrhythmic agents (e.g., amiodarone): require ECG monitoring.
NSAIDs: can attenuate blood‑pressure‑lowering response.
Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Frequently Asked Questions

Nebivolol Eg contains the beta‑blocker nebivolol and is prescribed to lower high blood pressure in adults. It may also be used as part of therapy for certain forms of heart failure and chronic stable angina, depending on the treating physician’s assessment.

Nebivolol selectively blocks β1‑adrenergic receptors, reducing heart rate and contractility, which lowers cardiac output. It also enhances nitric oxide release from the endothelium, causing vasodilation that further decreases systemic vascular resistance and blood pressure.

The dosage of Nebivolol Eg is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function and other medications. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of nebivolol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nebivolol Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is distinguished by its combined β1‑blockade and nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability compared with non‑vasodilating beta‑blockers such as atenolol or metoprolol. Clinical choice depends on individual patient characteristics and physician preference.

Nebivolol Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain its stability and potency.

Nebivolol Eg is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events can include severe bradycardia, heart block, bronchospasm in patients with asthma or COPD, and rare cases of hepatic dysfunction or allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as fainting, severe shortness of breath, or rash with swelling.

Nebivolol Eg is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or severe asthma/COPD unless a specialist advises otherwise.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 21 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.